Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Placebo and Active Comparator Controlled Phase 3a Study

Autor: Oncko B. van Vierssen Trip, Viktor Vik, Ingrid van der Putten-Slob, Christopher R. Chapple, Roberto Mario Scarpa, Bernard Gattegno, Simon Holmes, Salman Al-Shukri, José M. Martínez-Sagarra

Publikováno v: European Urology Supplements. 4:33-44

Objectives: This phase 3a study assessed the efficacy and safety of two different doses of a new formulation of tamsulosin (the oral controlled absorption system: OCAS) in comparison with placebo and the old modified release (MR) formulation of tamsu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e1b2232414765c90c9c6116fc8dcec4
https://doi.org/10.1016/j.eursup.2004.10.010

A phase II dose-ranging study of mirabegron in patients with overactive bladder

Autor: Chapple, Christopher R., Vladimir, Dvorak, Pjotr, Radziszewski, Philip Van Kerrebroeck, Jean Jacques Wyndaele, Brigitte, Bosman, Peter, Boerrigter, Ted, Drogendijk, Arwin, Ridder, Ingrid Van Der Putten Slob, Osamu, Yamaguchi, Carbone, Antonio

Publikováno v: International urogynecology journal
International Urogynecology Journal, 24(9), 1447-1458. Springer-Verlag London Ltd.
International Urogynecology Journal

Mirabegron is a potent and selective beta(3)-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. Patients completed a single-blinded, 2-week placebo run-in period f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a4faceb17aa81a3f005dfb77a72fc9
https://hdl.handle.net/10067/1107320151162165141